Tofacitinib in Pediatric Psoriasis: An Open-Label Trial to Study Its Safety and Efficacy in Children

Al-Mutairi, Nawaf; Nour, Tarek

doi:10.1159/000503062

Cited by 13 publications

(14 citation statements)

References 39 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Few studies have addressed the use of oral tofacitinib in the pediatric and adolescent population for AA 9,13,14 . Craiglow et al demonstrated a low prevalence of adverse effects in adolescent patients on tofacitinib 9 .…”

Section: Discussionmentioning

confidence: 99%

Oral tofacitinib for the treatment of alopecia areata in pediatric patients

Kibbie

Kines

Norris

et al. 2021

Pediatric Dermatology

View full text Add to dashboard Cite

Background Alopecia areata (AA) is characterized by the loss of hair, often in well‐demarcated areas. While the pathogenesis of AA is not entirely understood, it is known that CD8 T cell‐mediated destruction of the hair follicle occurs. There are no curative therapies for AA, although several therapies have been utilized with variable results. Oral tofacitinib, a JAK inhibitor, has been demonstrated to be efficacious and well tolerated in the treatment of adult AA. However, few studies have examined the clinical efficacy and tolerability of oral tofacitinib in the treatment of pediatric AA. Objective To summarize the clinical outcomes of pediatric patients with AA treated with oral tofacitinib at the University of Colorado Hospital Dermatology Clinic. Methods This is a retrospective case series conducted at the University of Colorado Hospital Dermatology Clinic. We included patients with a diagnosis of AA who were 18 years old or younger at the initiation of tofacitinib therapy. Demographics, treatment response, and adverse events were collected from electronic medical records. Results Eleven patients (seven females, four males) with AA presented to the University of Colorado Hospital Dermatology Clinic who were between the ages of 8 and 18 years. Eight patients (72.7%) experienced hair regrowth with oral tofacitinib, while three patients (27.3%) experienced minimal to no hair regrowth. There were no serious adverse events recorded in the study population during the observed treatment period. Conclusions Oral tofacitinib was clinically effective in the majority our of patients and well tolerated.

show abstract

Section: Discussionmentioning

confidence: 99%

Oral tofacitinib for the treatment of alopecia areata in pediatric patients

Kibbie

Kines

Norris

et al. 2021

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

“…At week 12, 55.32% achieved PASI 75, with 70.21% at week 36. No severe side effects were noted [107].…”

Section: Tofacitinibmentioning

confidence: 89%

Pediatric Psoriasis: From New Insights into Pathogenesis to Updates on Treatment

et al. 2021

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory systemic disease primarily affecting the skin, but which often involves considerable comorbidities as well. One-third of psoriasis cases start during childhood. In pediatric psoriasis, an association with several medical comorbidities is also indicated. Furthermore, because of its chronic nature and frequent relapses, psoriatic patients tend to require long-term treatment and experience negative impacts on their quality of life. Considering the different clinical characteristics of pediatric psoriasis, it has recently been presented that the pathogenesis of pediatric psoriasis is distinct from adult psoriasis. Treatment for pediatric psoriasis usually involves the same methods as for adults. However, most treatments in pediatric psoriasis are used off-label and research in this regard is still lacking. Targeted therapies involving newly developed biologics are also increasingly being applied to psoriasis in children. This review summarizes the clinical characteristics of pediatric psoriasis and focuses mainly on the updated concepts of pathogenesis and treatments in pediatric psoriasis. This was undertaken to widen the understanding of these relevant aspects and to provide better management of pediatric psoriasis by clinicians.

show abstract

“…Various cytokines released from dermal dendritic cells cause activation of T helper (Th)1 and Th17 cells, which release the cytokines causing proliferation of keratinocytes in epidermis. The activated Th1 lymphocytes secrete tumour necrosis factor‐α and IFN‐γ, while Th17 lymphocytes secrete IL‐17 24 …”

Section: Common Dermatosesmentioning

confidence: 99%

Tofacitinib in paediatric dermatoses: a narrative review

Agrawal

Panda

Das

2022

Clin Experimental Derm

View full text Add to dashboard Cite

Tofacitinib has revolutionized the treatment of numerous dermatological conditions in different age groups. However, evidence for its effectiveness, safety and tolerability in the paediatric population is limited. We performed a literature search, which showed that oral tofacitinib is a reliable option in refractory juvenile dermatomyositis, severe alopecia areata, atopic dermatitis and psoriasis. Topical tofacitinib is an effective option in vitiligo and halo naevus. The risk-benefit ratio should be assessed prior to consideration of this molecule. In this narrative review, we have attempted to present a summary of the evidence of using tofacitinib (oral and topical) in paediatric dermatoses.

show abstract

Tofacitinib in Pediatric Psoriasis: An Open-Label Trial to Study Its Safety and Efficacy in Children

Cited by 13 publications

References 39 publications

Oral tofacitinib for the treatment of alopecia areata in pediatric patients

Oral tofacitinib for the treatment of alopecia areata in pediatric patients

Pediatric Psoriasis: From New Insights into Pathogenesis to Updates on Treatment

Tofacitinib in paediatric dermatoses: a narrative review

Contact Info

Product

Resources

About